On December 26, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Syrimed reached an exclusive license and supply agreement of a skeletal muscle relaxation oral solution product (hereinafter referred to as "the product"). Under the terms of the agreement, Beimei will be responsible for the registration and commercialization of the product in China.

This product is used to relieve voluntary muscle spasm caused by multiple sclerosis, spinal cord tumor, motor neuron injury, cerebral palsy and other diseases. For the drugs used for the treatment, there are only solid tablets marketing on the market, while no oral liquid products are available to special population such as children in China. This product is designed in a dosage form specific for children, and can fill the blank in this field and meet the unmet clinical needs.

Spasticity is an abnormal increase in muscle tone or muscle stiffness due to damage to the neural pathways in the brain or spinal cord that control muscle movement. Among them, most children with spasticity are caused by cerebral palsy. According to incomplete statistics, children with cerebral palsy account for 2‰~4‰ of the newborn population in China. At present, there are no less than 6 million cases of cerebral palsy every year, and 60,000 new cases are added every year. Cerebral palsy is highly disabling, bringing heavy burdens to families and society, and its treatment is also one of the difficulties in medical industry.

This product is the most common and the first-line treatment for spasticity. The drug is one of the few drugs that are not dosed by weight in the pediatric population. Its pharmacokinetic properties are variable, and children are prone to the risk of underdosage or overdose when using solid dosage forms. As an oral liquid of skeletal muscle relaxants, this product addresses the problem of lack of dosage forms in the market, and provides a new option of administration for children with spasticity caused by cerebral palsy. It is expected to greatly improve the accessibility and treatment compliance of children with this indication.

The future cooperation with SyriMed is in line with the layout needs of Beimei in the field of children's nervous system. In the future, we will continue to develop the high-quality and suitable drugs for children, further enrich Beimei's porfolio, and solve the drug needs issue of Chinese children.

            About SyriMed

SyriMed is one of the UK's leading pharmaceutical companies. SyriMed is specialized in the development, licensing, manufacture and marketing of liquid medicines. It was established in Ruislip, West London in 2004. As of now, SyriMed has more than 100 marketing authorizations globally . All products on the market are developed by the company's R&D team, and the production is in compliance with GMP requirements. For more information, please visit its website at  https://www.syrimed.co.uk

            About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated. For more information, please visit our website at http://www.beimeiyaoye.com